Induction of apoptosis in renal cell carcinoma by reactive oxygen species: Involvement of extracellular signal-regulated kinase 1/2, p38δ/γ, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor

Molecular Pharmacology

Volumn 69, Issue 6, 2006, Pages 1879-1890

  Ambrose, Monica ^a   Ryan, Aideen ^a   O'Sullivan, Gerald C ^b   Dunne, Colum ^b   Barry, Orla P ^a,b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

^c University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 6 ANILINO 5,8 QUINOLINEQUINONE; ACETYLCYSTEINE; APOPTOSIS INDUCING FACTOR; CYCLOOXYGENASE 2; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; EPITHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DOWN-REGULATION; GENE EXPRESSION; HUMANS; KIDNEY NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 12; MITOGEN-ACTIVATED PROTEIN KINASE 13; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN TRANSPORT; REACTIVE OXYGEN SPECIES;

EID: 33745153132     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.020875     Document Type: Article

References (39)

1. Adler V, Yin Z, Tew KD, and Ronai Z (1999) Role of redox potential and reactive oxygen species in stress signaling. Oncogene 18:6104-6111.
2. Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27:177-186.
3. An J, Chen Y, and Huang Z (2004) Critical upstream signals of cytochrome c release induced by a novel Bcl-2 inhibitor. J Biol Chem 279:19133-19140.
4. Barry OP, Mullan B, Sheehan D, Kazanietz MG, Shanahan F, Collins JK, and O'Sullivan G (2001) Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J Biol Chem 276:15537-15546.
5. Beasley D, Schwartz JH, and Brenner BM (1991) Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Investig 87:602-608.
6. Bombrun A, Gerber P, Casi G, Terradillos O, Antonsson B, and Halazy S (2003) 3,6-Dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome c release via Bax channel modulation. J Med Chem 46:4365-4368.
7. Boring CC, Squires TS, Tong T, and Montgomery S (1994) Cancer statistics, 1994. CA Cancer J Clin 44:7-26.
8. Bowden ET, Stoica GE, and Wellstein A (2002) Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 277:35862-35868.
9. Braughler JM, Gilloteaux J, and Steggles AW (1982) Alterations in the subcellular distribution of guanylate cyclase and its responsiveness to nitric oxide in diethylstilbestrol-induced renal tumors. Cancer 50:78-84.
10. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198-1220.
11. Chen Q, Shinohara N, Abe T, Wanabe T, Nonomura K, and Koyanagi T (2004) Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 108:825-832.
12. Chiche JD, Schlutsmeyer SM, Bloch DB, de la Monte SM, Roberts JD Jr, Filippov G, Janssens SP, Rosenzweig A and Bloch KD (1998) Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem 273:34263-34271.
13. Cobb MH (1999) MAP kinase pathways. Prog Biophys Mol Biol 71:479-500.
14. Dong J, Ramachandiran S, Tikoo K, Jia Z, Lau SS, and Monks TJ (2004) EGFR-independent activation of p38 MAPK and EGFR-dependent activation of ERK1/2 are required for ROS-induced renal cell death. Am J Physiol 287:F1049-F1058.
15. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Grodeur GM, et al. (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124.
16. Gumpricht E, Dahl R, Devereaux MW, and Sokol RJ (2005) Licorice compounds glycyrrhizin and 18beta-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J Biol Chem 280:10556-10563.
17. Halliwell B and Whiteman M (2004) Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br J Pharmacol 142:231-255.
18. Hasegawa T, Bando A, Tsuchiya K, Abe S, Okamoto M, Kirima K, Ueno S, Yoshizumi M, Houchi H, and Tamaki T (2004) Enzymatic and nonenzymatic formation of reactive oxygen species from 6-anilino-5,8-quinolinequinone. Biochim Biophys Acta 1670:19-27.
19. Ho RC, Alcazar O, Fujii N, Hirschman MF, and Goodyear LJ (2004) p38gamma MAPK regulation of glucose transporter expression and glucose uptake in L6 myotubes and mouse skeletal muscle. Am J Physiol 286:R342-R349.
20. Kallio JP, Hirvikoski P, Helin H, Luukkaala T, Tammela TL, Kellokumpu-Lehtinen P, and Martikainen PM (2004) Renal cell carcinoma Mib-1, BAX and Bcl-2 expression and prognosis. J Urol 172:2158-2161.
21. Kamata H, Honda S, Maeda S, Chang L, Hirata H, and Karin M (2005) Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120:649-661.
22. Kuma Y, Campbell DG, and Cuenda A (2004) Identification of glycogen synthase as a new substrate for stress-activated protein kinase 2b/p38beta. Biochem J 379:133-139.
23. Lee YS and Wurster RD (1995) Mechanism of potentiation of LY83583-induced growth inhibition by sodium nitroprusside in human brain tumor cells. Cancer Chemother Pharmacol 36:341-344.
24. Lodygin D, Menssen A, and Hermeking H (2002) Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Investig 110:1717-1727.
25. Mertins SD, Myers TG, Hollingshead M, Dykes D, Bodde E, Tsai P, Jefferis CA, Gupta R, Linehan WM, Alley M, et al. (2001) Screening for and identification of novel agents directed at renal cell carcinoma. Clin Cancer Res 7:620-633.
26. Mizutani Y, Nakanishi H, Yamamoto K, Li YN, Matsubara H, Mikami K, Okihara K, Kawauchi A, Bonavida B, and Miki T (2005) Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 23:448-454.
27. Motzer RJ, Bander NH, and Nanus DN (1996) Renal-cell carcinoma. N Engl J Med 335:865-875.
28. Motzer RJ and Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408-417.
29. - cotransport in vascular smooth muscle cells. J Biol Chem 261:15461-15466.
30. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M, and Yoshida O (1995) Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55:4182-4187.
31. Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J, and Chen G (2003) p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem 278:4831-4839.
32. Schmidt MJ, Sawyer BD, Truex LL, Marshall WS, and Fleisch JH (1985) LY83583: an agent that lowers intracellular levels of cyclic guanosine 3′,5′-monophosphate. J Pharmacol Exp Ther 232:764-769.
33. Tourani J-M, Pfister C, Tubiani N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero J-M, et al. (2003) Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design-the Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 21:3987-3994.
34. Velarde V, de la Cerda PM, Duarte C, Arancibia F, Abbott E, Gonzalez A, Moreno F, and Jaffa AA (2004) Role of reactive oxygen species in bradykinin-induced proliferation of vascular smooth muscle cells. Biol Res 37:419-430.
35. Vuky J and Motzer R (2000) Cytokine therapy in renal cell cancer. J Urol Oncol 5:249-257.
36. Wang Z, Li Y, Liu ET, and Yu Q (2004) Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. Biochem Biophys Res Commun 322:609-613.
37. Wang X and Tournier C (2006) Regulation of cellular functions by the ERK5 signalling pathway Cell Signal 18:753-760.
38. Yang SH, Galanis A, and Sharrocks AD (1999) Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. Mol Cell Biol 19:4028-4038.
39. Yu C, Rahmani M, Almenara J, Sausville EA, Dent P, and Grant S (2004) Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene 23:1364-1376.